Keywords

canagliflozin, dapagliflozin, empagliflozin pharmacotherapy, SGLT2 inhibitors, sodium-glucose cotransporter-2 inhibitors, T2DM, type 2 diabetes mellitus

 

Authors

  1. Ashjian, Emily PharmD, BCPS, BCACP
  2. Tingen, Jeffrey PharmD, MBA, BCPS, BCACP, CDE

Abstract

Abstract: The number of patients with type 2 diabetes mellitus (T2DM) continues to increase in the United States. Glycemic control among patients with diabetes is important to prevent future complications, including microvascular and macrovascular disease. A novel class of medications, sodium-glucose cotransporter-2 inhibitors, presents an additional oral treatment option for patients with T2DM.